FIELD: chemistry; pharmaceutics.
SUBSTANCE: invention relates to a conjugated drug based on a tricyclic polypeptide, particularly a compound of formula (III), or a pharmaceutically acceptable salt thereof, and use thereof in treating solid tumours in which nectin-4 is overexpressed.
EFFECT: what is presented is a conjugated drug based on a tricyclic polypeptide for treating solid tumours in which nectin-4 is overexpressed.
10 cl, 4 dwg, 16 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PRODUCTION AND USE OF POLYPEPTIDE | 2022 |
|
RU2830694C2 |
| RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS AND THEIR USE | 2018 |
|
RU2804297C2 |
| POLY-LIGAND MEDICINAL CONJUGATES AND USE THEREOF | 2016 |
|
RU2722449C2 |
| PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | 2018 |
|
RU2807076C2 |
| DRUG BILIGAND CONJUGATE AND USE THEREOF | 2020 |
|
RU2820346C2 |
| PRODRUG CONTAINING A SELF-CLEAVABLE LINKER | 2018 |
|
RU2798085C2 |
| HOMODETIC CYCLIC PEPTIDES SPECIFICALLY ACTING ON α4β7 INTEGRIN | 2018 |
|
RU2773443C2 |
| CHIMERIC ANALOGS OF SOMATOSTATIN-DOPAMINE | 2002 |
|
RU2277539C2 |
| PRODRUG CONTAINING SELF-CLEAVABLE LINKER | 2014 |
|
RU2676324C2 |
| BENZO-N-HYDROXYAMIDE COMPOUNDS HAVING ANTI-TUMOR ACTIVITY | 2017 |
|
RU2737433C2 |
